A citation-based method for searching scientific literature

Ramona Dadu, Mimi N Hu, Elizabeth G Grubbs, Robert F Gagel. Recent Results Cancer Res 2015
Times Cited: 10







List of co-cited articles
24 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
877
70

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
685
50

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
988
30

Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Karin Frank-Raue, Friedhelm Raue. Recent Results Cancer Res 2015
29
20

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. J Clin Oncol 2010
352
20

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Bruce G Robinson, Luis Paz-Ares, Annetta Krebs, James Vasselli, Robert Haddad. J Clin Endocrinol Metab 2010
181
20

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.
Iván Plaza-Menacho, Luca Mologni, Elisa Sala, Carlo Gambacorti-Passerini, Anthony I Magee, Thera P Links, Robert M W Hofstra, David Barford, Clare M Isacke. J Biol Chem 2007
83
20


Targeting RET receptor tyrosine kinase activation in cancer.
John E Phay, Manisha H Shah. Clin Cancer Res 2010
103
20

Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.
Steven G Waguespack, Thereasa A Rich, Nancy D Perrier, Camilo Jimenez, Gilbert J Cote. Nat Rev Endocrinol 2011
64
20

Management of advanced medullary thyroid cancer.
Julien Hadoux, Furio Pacini, R Michael Tuttle, Martin Schlumberger. Lancet Diabetes Endocrinol 2016
64
20

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Nishant Agrawal, Yuchen Jiao, Mark Sausen, Rebecca Leary, Chetan Bettegowda, Nicholas J Roberts, Sheetal Bhan, Allen S Ho, Zubair Khan, Justin Bishop,[...]. J Clin Endocrinol Metab 2013
147
20

Medullary thyroid cancer: management guidelines of the American Thyroid Association.
Richard T Kloos, Charis Eng, Douglas B Evans, Gary L Francis, Robert F Gagel, Hossein Gharib, Jeffrey F Moley, Furio Pacini, Matthew D Ringel, Martin Schlumberger,[...]. Thyroid 2009
823
20


ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death.
Jaeseok Han, Sung Hoon Back, Junguk Hur, Yu-Hsuan Lin, Robert Gildersleeve, Jixiu Shan, Celvie L Yuan, Dawid Krokowski, Shiyu Wang, Maria Hatzoglou,[...]. Nat Cell Biol 2013
20

ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
Rozita Bagheri-Yarmand, Michelle D Williams, Elizabeth G Grubbs, Robert F Gagel. J Clin Endocrinol Metab 2017
13
20

The integrated stress response.
Karolina Pakos-Zebrucka, Izabela Koryga, Katarzyna Mnich, Mila Ljujic, Afshin Samali, Adrienne M Gorman. EMBO Rep 2016
997
20

Signal transduction by the receptor tyrosine kinase Ret.
D H van Weering, J L Bos. Recent Results Cancer Res 1998
57
20

A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis.
Rozita Bagheri-Yarmand, Krishna M Sinha, Anupama E Gururaj, Zamal Ahmed, Yasmeen Q Rizvi, Su-Chen Huang, John E Ladbury, Oliver Bogler, Michelle D Williams, Gilbert J Cote,[...]. J Biol Chem 2015
35
20

The GDNF/RET signaling pathway and human diseases.
M Takahashi. Cytokine Growth Factor Rev 2001
335
20

Thyroid Cancer: Role of RET and Beyond.
Francesca Carlomagno. Eur Thyroid J 2012
15
20

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Rossella Elisei, Barbara Cosci, Cristina Romei, Valeria Bottici, Giulia Renzini, Eleonora Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo,[...]. J Clin Endocrinol Metab 2008
327
20


Medullary thyroid carcinoma: management of lymph node metastases.
Jeffrey F Moley. J Natl Compr Canc Netw 2010
59
20



RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.
Nobuki Nakamura, J Aidan Carney, Long Jin, Sabine Kajita, Judit Pallares, Heyu Zhang, Xiang Qian, Thomas J Sebo, Lori A Erickson, Ricardo V Lloyd. Lab Invest 2005
80
10

Epigenomes as therapeutic targets.
Christopher A Hamm, Fabricio F Costa. Pharmacol Ther 2015
67
10

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
M-C Chen, C-H Chen, J-C Wang, A-C Tsai, J-P Liou, S-L Pan, C-M Teng. Cell Death Dis 2013
59
10

An introduction to small non-coding RNAs: miRNA and snoRNA.
Christopher L Holley, Veli K Topkara. Cardiovasc Drugs Ther 2011
67
10

DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
Sandra Rodríguez-Rodero, Agustín F Fernández, Juan Luís Fernández-Morera, Patricia Castro-Santos, Gustavo F Bayon, Cecilia Ferrero, Rocio G Urdinguio, Rocío Gonzalez-Marquez, Carlos Suarez, Iván Fernández-Vega,[...]. J Clin Endocrinol Metab 2013
84
10

MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility.
Marina N Nikiforova, George C Tseng, David Steward, Donna Diorio, Yuri E Nikiforov. J Clin Endocrinol Metab 2008
449
10


New molecular targeted therapies in thyroid cancer.
Amalia Milano, Maria G Chiofalo, Maria Basile, Antonella Salzano de Luna, Luciano Pezzullo, Francesco Caponigro. Anticancer Drugs 2006
18
10

The PDCD4/miR-21 pathway in medullary thyroid carcinoma.
Gianmaria Pennelli, Francesca Galuppini, Susi Barollo, Elisabetta Cavedon, Loris Bertazza, Matteo Fassan, Vincenza Guzzardo, Maria Rosa Pelizzo, Massimo Rugge, Caterina Mian. Hum Pathol 2015
51
10


Noncoding RNA blockade of autophagy is therapeutic in medullary thyroid cancer.
Justin S Gundara, JingTing Zhao, Anthony J Gill, James C Lee, Leigh Delbridge, Bruce G Robinson, Catriona McLean, Jonathan Serpell, Stan B Sidhu. Cancer Med 2015
22
10

Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells.
T Angrisano, S Sacchetti, F Natale, A Cerrato, R Pero, S Keller, S Peluso, B Perillo, V E Avvedimento, A Fusco,[...]. Nucleic Acids Res 2011
39
10

HDAC Inhibitors as Novel Anti-Cancer Therapeutics.
Cristabelle De Souza, Biswa Prasun Chatterji. Recent Pat Anticancer Drug Discov 2015
89
10

PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
Gloria Irene Manfredi, Alessandra Dicitore, Germano Gaudenzi, Michele Caraglia, Luca Persani, Giovanni Vitale. Endocrine 2015
77
10

Cancer epigenetics: new therapies and new challenges.
Eleftheria Hatzimichael, Tim Crook. J Drug Deliv 2013
48
10

Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
Wenwen Duan, Jin Li, Elizabeth S Inks, C James Chou, Yuping Jia, Xiaojing Chu, Xiaoyang Li, Wenfang Xu, Yingjie Zhang. J Med Chem 2015
55
10

A miRNA signature associated with human metastatic medullary thyroid carcinoma.
Libero Santarpia, George A Calin, Liana Adam, Lei Ye, Alfredo Fusco, Serena Giunti, Christina Thaller, Laura Paladini, Xinna Zhang, Camilo Jimenez,[...]. Endocr Relat Cancer 2013
66
10

Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.
Joel T Adler, Daniel G Hottinger, Muthusamy Kunnimalaiyaan, Herbert Chen. J Surg Res 2010
29
10

Expression of the active Notch1 decreases MTC tumor growth in vivo.
Renata Jaskula-Sztul, Pongthep Pisarnturakit, Michael Landowski, Herbert Chen, Muthusamy Kunnimalaiyaan. J Surg Res 2011
20
10

Current approaches and perspectives in the therapy of medullary thyroid carcinoma.
G Vitale, M Caraglia, A Ciccarelli, G Lupoli, A Abbruzzese, P Tagliaferri, G Lupoli. Cancer 2001
93
10

Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection.
M N Soler, P Bobé, K Benihoud, G Lemaire, B A Roos, S Lausson. J Gene Med 2000
42
10

MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.
Deepak Abraham, Nicole Jackson, Justin S Gundara, JingTing Zhao, Anthony J Gill, Leigh Delbridge, Bruce G Robinson, Stan B Sidhu. Clin Cancer Res 2011
116
10


Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction.
Renata Jaskula-Sztul, Jacob Eide, Sara Tesfazghi, Ajitha Dammalapati, April D Harrison, Xiao-Min Yu, Casi Scheinebeck, Gabrielle Winston-McPherson, Kevin R Kupcho, Matthew B Robers,[...]. Mol Cancer Ther 2015
36
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.